

## COMPANY OVERVIEW

Xenetic Biosciences, Inc. is a biopharmaceutical company focused on progressing XCART™, a personalized CAR T platform technology engineered to target patient-specific tumor neoantigens. The Company is advancing cell-based therapeutics targeting the unique B-cell receptor on the surface of an individual patient's malignant tumor cells for the treatment of B-cell lymphomas. XCART™ has the potential to fuel a robust pipeline of therapeutic assets targeting high-value oncology indications.

Xenetic is leveraging PolyXen®, its proprietary drug delivery platform, by partnering with biotechnology and pharmaceutical companies. PolyXen® has demonstrated its ability to improve the half-life and other pharmacological properties of next-generation biologic drugs. The Company has an exclusive license agreement with Takeda Pharmaceuticals Co. Ltd. in the field of coagulation disorders and receives royalty payments under this agreement. Additionally, Xenetic's partner, PJSC Pharmsynthez ("Pharmsynthez"), is leveraging the Company's PolyXen® technology to improve the pharmacological properties of its Epolong (erythropoietin and polysialic acid conjugate) product candidate pursuant to a royalty-bearing collaboration agreement between the Company's wholly owned subsidiary, Lipoxen Technologies Limited, and Pharmsynthez's wholly owned subsidiary, SynBio LLC. Pharmsynthez has reported that it has started the registration phase of Epolong by filing a registration dossier to obtain approval of Epolong in Russia for the treatment of anemia in patients with chronic kidney disease. The registration dossier is based on previously reported data from Pharmsynthez's Phase 3 clinical trials of Epolong in Russia, which reportedly demonstrated the efficacy of Epolong and its potential to reduce side effects.

## RECENT NEWS

### [Xenetic Biosciences, Inc. Receives Approval to Commence Exploratory Study of XCART\(TM\)](#)

Mar 29 2021, 8:05 AM EDT

### [Xenetic Biosciences, Inc. Reports Fourth Quarter and Full Year 2020 Financial Results](#)

Mar 17 2021, 8:00 AM EDT

## STOCK OVERVIEW

Symbol	XBIO
Exchange	Nasdaq
Market Cap	11.71m
Last Price	\$1.86
52-Week Range	\$0.76 - \$5.85

05/07/2021 04:00 PM EDT

## INVESTOR RELATIONS

JTC Team, LLC.  
Jenene Thomas  
T: 833-475-8247  
[xbio@jtcir.com](mailto:xbio@jtcir.com)

## MANAGEMENT TEAM

**Jeffrey F. Eisenberg**  
Chief Executive Officer

**Curtis Lockshin, Ph.D.**  
Chief Scientific Officer

**James F. Parslow**  
Chief Financial Officer

## XENETIC BIOSCIENCES, INC.

40 Speen Street  
Suite 102  
Framingham, MA 01701  
US

Except for the historical information contained here in, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on form 10-K and it's quarterly reports on Form 10-Q. The company does not undertake any obligation to update forward-looking statements. All trademarks and brand name are the property of their respective companies.